The DNA base editing technology developed in the lab of David Liu, professor of chemistry and chemical biology, emerged as a core technology platform at Beam Therapeutics, which officially launched with up to $87 million in a cumulative series A financing. The multi-stage round will help Beam "go broad" across multiple years of drug discovery, according to CEO John Evans, to develop precision genetic medicines by making edits to individual base pairs in the genetic code. The funding also will support a cryptically described "affiliated entity."